Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

935 790

Amortization of deferred financing

charges 131 110 87

Interest income (542) (503) (374)

-------------------------------------------------------------------------

Loss from operation for the period 12,543 9,638 17,909

-------------------------------------------------------------------------

(Gain) on sale of shares (6,299)

-------------------------------------------------------------------------

Net (earnings)/loss and other

comprehensive income for the

period 6,244 9,638 17,909

-------------------------------------------------------------------------

Basic and diluted loss per common

share $ 0.03 $ 0.05 $ 0.10

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number of common

shares outstanding used in the

calculation of basic and diluted

loss per share 215,084 204,860 173,523

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Note re the financial statement information above:

On July 10, 2007 (the "Arrangement Date"), the Company completed a plan of arrangement and corporate reorganization with 4325231 Canada Inc., formerly Lorus Therapeutics Inc., ("Old Lorus"), 6707157 Canada Inc. and Pinnacle International Lands Inc (the "Arrangement"). As a result of the plan of arrangement and reorganization, among other things, each common share of Old Lorus was exchanged for one common share of the Company and the assets (excluding certain future ta
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at Dallas ... in Phoenix, AZ , today announce an ... for patients with a broad range of cancers. Aligning the ... trials and access to technology to drive the development of ... across Baylor Scott & White Health,s 49 hospitals ...
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Patent Offering, ... method for diagnostic or therapeutic imaging within a body ... uses an endoscope having a low cost, single-use disposable ... filing date was October 18, 2013 and the patent ... technology enables the physician to customize the lighting and ...
(Date:5/21/2015)... 21, 2015 Veolia’s environmental monitoring ... North American distribution agreement with VWR to distribute ... With more than 160 years of experience, VWR, ... for laboratory and production facilities, has cultivated a ... differentiated services to enable science. Endetec’s TECTA™ ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Correction Continues after Big Move - BrokerBank Securities, Inc. 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... Society of Forensic Toxicologists (SOFT) recognizes the recent ... Strengthening Forensic Science in the United States: A ... within the forensic sciences where improvements may be ... education, training, accreditation and certification in forensic science. ...
... superior to synthetic HRT with greater cardiovascular benefits ... 23 The most comprehensive analysis to date, ... peer-reviewed publication for practicing clinicians, showed that bioidentical ... are more efficacious than their synthetic counterparts. Conducted ...
... BOZEN, Italy, February 23 Health Robotics ... a definitive agreement whereby Can-Med,has acquired the ... in Armenia, Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, ... first and only automated, point-of-care-distributed, and fail-safe,robotic ...
Cached Biology Technology:The Society of Forensic Toxicologists Comments on the National Academy of Sciences' Report on 'Strengthening Forensic Science in the United States' 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 3Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... 2010) The Association for Molecular Pathology (AMP) invites ... Annual Meeting and Exhibits and learn about the latest ... four-day event will feature more than 100 corporate exhibits, ... sessions. The keynote speaker is the distinguished recipient of ...
... Chemicals pervade our lives. While the benefits to society ... enabling safer, more efficient and more convenient consumer products ... side. Today, a growing awareness of the risks posed ... stimulated intensive investigations into their lifecycle and the unintended ...
... women who undergo in vitro fertilization (IVF) procedures suffer from ... therapy involved in IVF procedures is primarily responsible for this. ... this is true, other factors are even more influential. ... University,s Sackler Faculty of Medicine and the Sourasky Medical Center ...
Cached Biology News:New book examines health and environmental impacts of common (and not-so-common) chemicals 2New book examines health and environmental impacts of common (and not-so-common) chemicals 3Overcoming the IVF baby blues 2Overcoming the IVF baby blues 3
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Biology Products: